Pelvic Inflammatory Disease Therapeutics Market

Pelvic Inflammatory Disease Therapeutics Market: Global Industry Analysis 2013 - 2017 and Opportunity Assessment; 2018 - 2028

  • Ongoing
  • April 2020
  • REP-GB-6950
  • PDF PPT EXCEL
Pelvic Inflammatory Disease Therapeutics Market
  • SELECT LICENSE TYPE :

  • US$5,000
  • US$7,500
  • US$10,000

This Pelvic Inflammatory Disease Therapeutics market study offers a comprehensive analysis of the business models, key strategies, and respective market shares of some of the most prominent players in this landscape. Along with an in-depth commentary on the key influencing factors, market statistics in terms of revenues, segment-wise data, region-wise data, and country-wise data are offered in the full study. This study is one of the most comprehensive documentation that captures all the facets of the evolving Pelvic Inflammatory Disease Therapeutics market.


Pelvic Inflammatory Disease Therapeutics: Market Insights

Pelvic Inflammatory disease is the infection of the upper female reproductive system. It can also be defined as the acute manifestation of ascending genital-tract infection that may involve the endometrium, fallopian tubes, and the adjacent pelvic structures. The condition generally occurs in sexually active women especially during their fertile years. Sexually transmitted organisms such as Neisseria gonorrhoeae and Chlamydia trachomatis are some of the general cause of pelvic inflammatory disease. However microorganisms that can be a part of the virginal flora such as Gardnerella vaginalis, Haemophilus influenza and Streptococcus agalactiae can also cause PID.

The diagnosis of the pelvic inflammatory disease includes a pelvic examination that may detect tenderness and may be a lump. Further pelvic swabs could be tested for the presence of gonorrhea and chlamydia. Blood tests can also be used for the detection of pelvic inflammatory disease. When the diagnosis is not certain other procedures may be done for confirmation such as laparoscopy and ultrasound. In most cases pelvic inflammatory disease clear up after 10 to 14 days of antibiotic treatment. 

The primary pelvic inflammatory disease therapeutics is antibiotics. These antibiotics could be administered orally or intravenously. Women with severe infection may need to be hospitalized for the administration of antibiotics intravenously. In extreme severe conditions that don’t improve even with the administration of antibiotics may require surgery to cure the infection.

Market Growth Analysis

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

Need granular data and specific insights that are hard to get?

Pelvic Inflammatory Disease Therapeutics: Market Dynamics

Growing awareness of pelvic inflammatory disease among women is driving the diagnosis rate there by resulting in more number of women being treated for the same. Furthermore the simple and very effective oral and intramuscular treatment as the first line treatment drives the adoption rate of the treatment. Increase in number of women in their fertile period ie. 20-24 years when the risk of developing pelvic inflammatory disease is rising across the world is another factor that drives the growth of the pelvic inflammatory disease therapeutics market. Furthermore, the improved healthcare conditions across the globe is another factor that drives the growth of the pelvic inflammatory disease therapeutic market. However misdiagnosis and the use of preventive methods may hinder the market growth of pelvic inflammatory disease therapeutics. Furthermore one on the greatest risk and challenge is the development of resistant strains of microorganisms that may hinder the market growth as antibiotics is the primary treatment for pelvic inflammatory disease.

Pelvic Inflammatory Disease Therapeutics Market: Overview

The CDC (Center for Disease Control and Prevention recommends the first line treatment of pelvic inflammatory disease with a cephalosporin along with doxycycline. A combination of oral and intramuscular therapy is generally recommended to patients with mild to moderate pelvic inflammatory disease. Because of the increasing widespread resistance, the CDC doesn’t recommend routine use of fluoroquinolone antibiotics in the U.S. In Europe the standard first line treatment for pelvic inflammatory disease continue to include ofloxacin.

Pelvic Inflammatory Disease Therapeutics Market: Region-wise Outlook

On the basis of geography, global pelvic inflammatory disease therapeutic market is segmented into seven key regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia Pacific excluding Japan, Japan, and Middle East & Africa. North America is projected to hold largest shares in the global pelvic inflammatory disease therapeutic market primarily due to growing awareness about pelvic inflammatory disease, and improved healthcare scenario.

Pelvic Inflammatory Disease Therapeutics Market: Key Players

Some of the key players present in global pelvic inflammatory disease therapeutics market are Mayne Pharma, Pfizer, AstraZeneca Pharmaceuticals, Janssen Pharmaceuticals, Inc. Sanofi and Merck & Co., Inc. others.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.

The report covers exhaust analysis on:

  • Market Segments
  • Market Dynamics
  • Market Size
  • Supply & Demand
  • Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Technology
  • Value Chain

Regional analysis includes:

  • North America (U.S., Canada)
  • Latin America (Mexico. Brazil)
  • Western Europe (Germany, Italy, France, U.K, Spain)
  • Eastern Europe (Poland, Russia)
  • Asia Pacific (China, India, ASEAN, Australia & New Zealand)
  • Japan
  • Middle East and Africa (GCC Countries, S. Africa, Northern Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Unique Requirements? Customize this Report

  • Customize by Region, Country, Application, Product, & other segments
  • Integrate our Insights with your Existing Data
  • Determine the scope of the study to suit your requirements

Let FMI Help You!

  • Gain Insights on Key Pelvic Inflammatory Disease Therapeutics Market Impacting Forces
  • Know the Winning Strategies of Market Leaders
  • Get Deep-Dive Analysis on Each Segment
  • Identify the Sources that will Drive Top-Line Revenue

Pelvic Inflammatory Disease Therapeutics Market: Segmentation

The global pelvic inflammatory disease therapeutics market is segmented by administration, by drug type and distribution channel:

Segmentation by Administration

  • Oral
  • Intramuscular
  • Intravenous

Segmentation by Drug Type

  • Cephalosporin
  • Doxycycline
  • Fluoroquinolone
  • Others

Segmentation by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • E-Commerce

Report Highlights:

  • Detailed overview of parent market
  • Changing market dynamics in the industry
  • In-depth market segmentation
  • Historical, current, and projected market size in terms of volume and value
  • Recent industry trends and developments
  • Competitive landscape
  • Strategies of key players and products offered
  • Potential and niche segments, geographical regions exhibiting promising growth
  • A neutral perspective on market performance
  • Must-have information for market players to sustain and enhance their market footprint
Frequently Asked Questions

Why choose FMI?
  • With a global presence and a trusted partner to several Fortune 500 firms, FMI covers 1 billion+ data points to build a diversified portfolio for market benchmarking
  • Market Reports researched and peer reviewed by industry experts from across the globe
  • We follow a multi-dimensional method of analysis monitoring a three-layer data validation process
  • In addition to demand-side market assessment, our data triangulation methodology involves supply-side research
  • Primary research includes mandatory field interviews with stakeholders involved
  • Customizing reports according to client specification is also our forte
  • The current and future market size, covering each aspect and nuanced trends across key national and geographic markets
  • An overview of the market report, providing an imperative visual of the varied market subdivisions and overall forecast statistics in terms of value and volume
  • Extensive database and key dynamics elevating the market with varied verticals associated
  • Underlying Pelvic Inflammatory Disease Therapeutics Market forces that are compelling consumers or businesses to purchase the product
  • How novel technologies and consumer-centric innovations will create new value-adding opportunities for companies active in the Pelvic Inflammatory Disease Therapeutics Market
  • What will be environment and regulatory impacts on the market over the next decade
  • Investment Feasibility Matrix - It shows returns on investment, level of competition, success rate of investment, and potential risks associated with the market. The analysis shows that the competition is high in the established market, while the returns for short-term investment are also taken into consideration
  • Relative Maturity Mapping – The relative maturity is measured according to three growth phases (growth, maturity, decline)
  • Relative PLC (Product Life Cycle) – Analysis of the emergence of prominent players and competitive test prices which are driving factors behind every market. (expected market behavior, observed market behavior, expected market performance, observed market performance)
Get in touch
Harish Tiwari

Harish Tiwari

Global Head - Business Development

Pranay Mhaisekar

Pranay Mhaisekar

Business Development

* indicates mandatory fields
Our Clients

Request Sample Request customization Request Methodology